G. Mears

HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine

L. Old, D. Valmori, B. Dupont, 2009, Clinical Cancer Research.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

S. Vogel, S. Adams, A. Pavlick, 2007, Proceedings of the National Academy of Sciences.

Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors

L. Old, D. Valmori, N. Bhardwaj, 2009, Journal of immunotherapy.

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire

L. Old, D. Valmori, N. Bhardwaj, 2009, Clinical Cancer Research.

Human MDR gene transfer in patients with advanced cancer.

C. Hesdorffer, K. Antman, A. Bank, 1994, Human gene therapy.

Preferential binding of beta s globin chains associated with stroma in sickle cell disorders.

A. Bank, J. O'Donnell, C. Natta, 1974, The Journal of clinical investigation.

B-cell lymphoma with pseudopapillary features, myxoid changes and lack of CD20 expression: a diagnostic pitfall

G. Bhagat, B. Alobeid, P. Raciti, 2015, Leukemia & lymphoma.

Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire

L. Old, D. Valmori, N. Bhardwaj, 2009, Clinical Cancer Research.